BioWorld MedTech

Feb. 20, 2013

SEMDA 2013: Leahey: med-tech firms' voices still matter despite difficulties

ATLANTA — Some would say that in recent years the landscape for med-tech has been littered with difficulties and challenges often resulting in many devicemakers feeling as if their voice has been diminished. Read More

NewCo on the Go: ForeCYTE test like Pap smear for breast cancer

Report from Europe: Dune Medical in compliance for next-gen MarginProbe

Washington roundup: Neiman Institute offers rubric for evaluating repeat imaging

Financings roundup: PolyActiva raises more than $9M in Series B funding round

Agreements/contracts: Laser Spine partners with Marodyne for LivMD device

Deals roundup: Liaison sees opportunities in HIT via Ignis acquisition

HIT roundup: EMH Healthcare goes live on Capsule's MVP

Med-Tech Notes

People in the News

Product Briefs

MDD's Oncology Extra

Today's news in brief

BioWorld

BioWorld briefs for April 15, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 15, 2025.

Caution tape displaying US flag, tariffs

Biopharma exempt from US reciprocal tariffs, but not untouched

BioWorld

At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...

Antibodies binding to spike proteins on the surface of SARS-CoV-2 virus

Australian researchers discover new compound to treat long COVID

BioWorld

Researchers have developed a new compound that can prevent long COVID symptoms in mice that could lead to a future drug for the debilitating condition in humans....

Blood glucose chart and monitor, stethoscope, injector pen

Hightide’s HTD-1801 meets phase III endpoints in type 2 diabetes

BioWorld

Hightide Therapeutics Inc.’s berberine ursodeoxycholate (HTD-1801) met primary and secondary endpoints in the Symphony 1 and Symphony 2 phase III trials in type 2...